HYBCELL TECHNOLOGY

 Multiplexed immuno-tests provide quantitative evidence of a whole range of parameters - which are all relevant for the same clinical diagnose.  For example the inflammation and organ status of a patient or the consumption of a number of different drugs (of abuse) can be tested in parallel. Therefore these tests are well suited for monitoring over a longer period of time or broad screenings of different samples (urine, serum, saliva).

 

Celeras Dx has developed a complete and entirely new multiplex technology based upon the principle of microarrays. The hybcell – the only cylindrical microarray available throughout the world – delivers speedy and reliable results with minimal hands-on.

 

The sample is pipetted into the hybcell together with a reaction mix. The device - the hyborg - processes the tests completely autonomous.

 

The tests are based upon the principle of competitive immunoassays. Drug molecules in the sample compete with fluorescence-labelled competitor antigens (a drug-conjugate compound of the reaction mix) to bind to immobilised antibodies on the hybcell's surface. The higher the concentration of drug in the sample, the fewer competitor-antigens bind to these antibodies on the surface. Non-binding competitor-antigens are removed during a washing step. Since the competitor-antigens are labelled with fluorescent dyes, the signal is reduced if the parameter (e.g. an inflammation status or a drug) is present in the sample. The hyborg software calculates the quantities of present drugs and compiles a report.

 

 

The hyborg – the completely automated device – carries out processing of the tests (in accordance to uploaded protocols) without any intervention by the user.